However, to draw far-reaching conclusions about the effectiveness of the drugs too early.
Researchers at UT Health in San Antonio, that collaborate with Mayo clinic and Medical school of Wake forest University, first published the results of treatment of deadly disease in people with medication called senation. The results were published in the journal EBioMedicine, informs Rus.Media.
Senate – these are the best medicine against aging (Engl. senolytics from senile – senile and lytic – destructive) – they are able precisely to initiate the death of elderly cells. The fact that the process of cleansing the body of old cells slows down with age, damaged cells persist and become toxic to surrounding tissues. This contributes to the development of multiple age-related diseases, including idiopathic pulmonary fibrosis (IPF), which leads to scarring in the lungs.
IPF is a devastating and progressive lung disease with an average survival of less than five years after diagnosis. Usually the disease affects adults older than 60 years. In fact, the only treatment option is lung transplantation, but it is not always available.
In the first pilot study involved 14 older people with a diagnosis of IPF from mild to moderate severity. Each participant received two senation drugs dasatinib and quercetin. Drugs taken orally for three consecutive days of the week, and this was repeated for three consecutive weeks (nine doses).
The research team measured biochemical markers before and after the introduction senatev and weekly conducted a thorough survey on the quality of life and side effects to obtain preliminary evidence of safety and tolerability. The team also evaluated the markers of physical function, including the six-minute walk distance, walking speed, number of repetitions to get up to sit in the chair, the index of bone fragility based on clinical tests, and biological analyses of proteins that are secreted toxic cells and associated with aging.
The most consistent improvement after senation therapy was observed in the mobility of the participants. The six-minute walk test, repetition sit-to stand up and other indicators were significantly improved after completion of treatment. The majority of patients showed an increase in the mobility by more than 5 %. Other markers of physical function, including lung function, has not changed.
Still no drug therapy, including available preparations Antipas, never gave similar results in patients with IPF, especially the increase in the distance traveled in 6 minutes. In this experimental study, the distance of walking has increased by an average of 21.5 meters.
The most common side effects reported by patients after treatment were respiratory symptoms such as cough and shortness of breath, gastrointestinal discomfort or heartburn.
At the moment, dasatinib and quercetin approved by the FDA. They are effective in eliminating aging cells of different types. This same combination of drugs in animal models have improved the course of Alzheimer’s disease.
However, to draw far-reaching conclusions about the effectiveness of the drugs too early. First, the pilot study was small (14 patients), and secondly, the study was not included a control group of patients with IPF who took a placebo, and not Senate. However, the success of the mini-experiment gives the possibility of attracting larger number of participants to obtain more conclusive results.